Predictors of long-term response and survival in patients with extensive stage small cell lung cancer (ES-SCLC) receiving atezolizumab plus chemotherapy in a real-world setting (IFCT-1905 CLINATEZO)

Category Primary study
ConferenceEuropean Lung Cancer Congress (ELCC) 2025
Year 2025
This article has no abstract
Epistemonikos ID: 4ba96e9e0faace2698034ca96e16c0b332fcfef5
First added on: Jan 22, 2026